By Gilang Cahya 
A groundbreaking study originating from the UCLA Health Jonsson Comprehensive Cancer Center is poised to reshape the understanding and management of high-risk, nonmetastatic hormone-sensitive prostate cancer. Researchers have discovered that a significant proportion of these patients, previously believed to have localized disease, actually harbor metastatic cancer when assessed with cutting-edge prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging. This finding suggests that traditional imaging modalities may be significantly underestimating the true extent of cancer spread in a substantial number of cases, potentially leading to suboptimal treatment decisions.
Rethinking Staging with PSMA-PET Imaging
The study, meticulously detailed in the esteemed journal JAMA Network Open, analyzed data from 182 patients with high-risk recurrent prostate cancer. Crucially, these individuals were initially categorized as having disease confined to the prostate and were eligible for the pivotal EMBARK clinical trial. The EMBARK trial, a significant landmark in prostate cancer treatment, demonstrated that the addition of enzalutamide, a potent hormone therapy, to androgen deprivation therapy significantly improved metastasis-free survival. However, the patient selection for EMBARK relied on conventional imaging techniques, which, according to the new UCLA research, may have missed the presence of distant cancer spread in a considerable percentage of participants.
The core of the UCLA study’s revelation lies in the stark contrast between conventional imaging and the advanced capabilities of PSMA-PET. PSMA-PET utilizes minuscule amounts of radioactive tracers, specifically designed to bind to prostate-specific membrane antigen (PSMA), a protein that is highly expressed on the surface of prostate cancer cells. When these radiotracers attach to the cancer cells, they emit signals that are detected by a PET scanner, creating highly detailed images that reveal the biological activity of the cancer. Unlike conventional imaging methods, such as CT scans or bone scans, which primarily provide anatomical information about the size and location of tumors, PSMA-PET offers functional imaging, offering insights into the metabolic activity and spread of the disease.
The Magnitude of the Discrepancy
The findings from the UCLA investigation are striking. When the 182 patients were re-evaluated using PSMA-PET imaging, a remarkable 46% were found to have metastatic disease, despite conventional imaging having indicated no evidence of cancer spread. This means that nearly half of the patients considered to have localized disease were, in fact, experiencing the cancer’s spread to other parts of the body.
Further dissecting these results, the study revealed that 24% of these patients exhibited five or more metastatic lesions that had been entirely missed by traditional imaging techniques. This highlights a significant gap in diagnostic accuracy, suggesting that a substantial number of high-risk prostate cancer patients might be entering treatment paradigms without a complete understanding of their disease’s full scope.
Dr. Jeremie Calais, the senior author of the study, director of the Ahmanson Translational Theranostics Division’s clinical research program, and associate professor at the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, emphasized the critical implications of these findings. "Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," Dr. Calais stated. He underscored that this advanced imaging technology is not merely an incremental improvement but a fundamental shift in how prostate cancer staging is approached.
Dr. Adrien Holzgreve, a visiting assistant professor at the David Geffen School of Medicine and the first author of the study, echoed Dr. Calais’s sentiments, expressing surprise at the sheer volume of missed metastatic findings. "We anticipated that PSMA-PET would detect more suspicious findings compared to conventional imaging," Dr. Holzgreve commented. "However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases." This observation underscores the potential for PSMA-PET to redefine patient eligibility for clinical trials and, consequently, influence the evidence base for future treatment guidelines.
Historical Context and the Evolution of Prostate Cancer Imaging
The landscape of prostate cancer detection and management has evolved considerably over the decades. Initially, diagnosis relied heavily on digital rectal examinations (DREs) and prostate-specific antigen (PSA) blood tests. The advent of transrectal ultrasound (TRUS)-guided biopsies further refined the diagnostic process, allowing for tissue sampling. For decades, conventional imaging techniques like CT scans and bone scans have been the standard for staging prostate cancer, particularly in identifying the spread of disease. However, these modalities have inherent limitations, especially in detecting small or subtle metastatic lesions, which can be particularly challenging in the context of prostate cancer.
The development of PSMA-PET imaging represents a significant leap forward. PSMA is a transmembrane protein that is upregulated in prostate cancer cells and is also present in normal tissues like the salivary glands and kidneys, but at much lower levels. The targeted nature of PSMA-PET tracers allows for the visualization of even small clusters of cancer cells that might be undetectable by conventional methods. This functional imaging capability provides a more sensitive and specific assessment of disease burden.
The clinical adoption of PSMA-PET has been a gradual but transformative process. While its diagnostic utility has become increasingly recognized, its integration into treatment decision-making and patient selection for clinical trials has lagged behind its imaging capabilities. This is partly due to the historical reliance on data from trials that did not incorporate PSMA-PET. The UCLA study directly addresses this disconnect, demonstrating the real-world impact of PSMA-PET on patient stratification and potentially on treatment efficacy.
Implications for Treatment and Future Research
The implications of these findings are far-reaching and multifaceted. Firstly, the study challenges the very definition of "nonmetastatic" disease in high-risk prostate cancer patients. If a significant portion of patients categorized as nonmetastatic actually have microscopic or even macroscopic metastases, then treatment strategies that are designed for localized disease may be less effective than anticipated. This could lead to a higher rate of treatment failure and disease progression in these patients.
The study’s results strongly advocate for the routine inclusion of PSMA-PET imaging in the staging of high-risk prostate cancer patients. This could lead to more accurate patient selection for clinical trials, ensuring that trials are enrolling patients with a truly comparable disease burden. Furthermore, it opens the door to more personalized treatment approaches. For patients identified with metastatic disease by PSMA-PET, new therapeutic avenues may become available. These could include targeted radiotherapies, such as PSMA-targeted radionuclide therapy (e.g., Lutetium-177 PSMA therapy), which can deliver radiation directly to cancer cells expressing PSMA, potentially offering a more effective and less toxic treatment option compared to systemic therapies.
The findings also raise important questions about the current standard of care. If PSMA-PET is significantly more accurate, should it become the primary imaging modality for staging high-risk prostate cancer? The UCLA researchers believe so, and their work provides compelling evidence to support this shift. "These results challenge the interpretation of previous studies, like the EMBARK trial, and support the inclusion of PSMA-PET for patient selection in clinical and trial interventions in prostate cancer in future major industry-sponsored clinical trials," the study authors conclude.
Moving Forward: Ongoing Research and Clinical Integration
UCLA is at the forefront of this evolving field, with ongoing research dedicated to further elucidating the role and impact of PSMA-PET imaging in prostate cancer management. The team is actively analyzing follow-up data from four UCLA-led clinical trials. This analysis aims to meticulously track how PSMA-PET findings have influenced treatment decisions made by clinicians and, crucially, how these decisions have ultimately affected patient outcomes.
Beyond UCLA’s internal initiatives, the researchers are also involved in a large-scale international consortium that is examining over 6,000 patients. This collaborative effort focuses on investigating the prognostic value of PSMA-PET, seeking to understand how the information gleaned from this imaging technique can predict the future course of the disease and the likelihood of treatment success.
While the current findings are highly encouraging, Dr. Calais emphasizes that further high-quality prospective data are essential to definitively establish the superiority of PSMA-PET for treatment guidance in terms of patient outcomes. "We have good rationales to assume that it is helpful to primarily rely on PSMA-PET findings," Dr. Holzgreve stated. "But more high-quality prospective data would be needed to claim superiority of PSMA-PET for treatment-guidance in terms of patient outcome. However, we are confident PSMA-PET will continue to advance prostate cancer staging and guide personalized therapies."
The journey of integrating new imaging technologies into standard clinical practice is often complex, involving regulatory approvals, reimbursement policies, and the need for extensive physician education. However, the compelling evidence presented by the UCLA study suggests that PSMA-PET is not just an investigational tool but a vital component for accurate prostate cancer staging. Its ability to uncover hidden metastases has the potential to revolutionize how high-risk prostate cancer is diagnosed, staged, and ultimately treated, paving the way for more effective and personalized care for patients. The ongoing research at UCLA and within the broader scientific community will be critical in solidifying PSMA-PET’s place as a cornerstone in the fight against prostate cancer.